更新版EARL协调化对淋巴瘤18F-FDG PET-CT的Deauville评分影响
使用SUVmax时Q.Clear与EARLlower/EARLupper的DS差异显著(p<0.0001),5例Q.Clear判定的非缓解者(DS 4-5)在现行EARL推荐下被归为缓解者(DS 1-3)。
要点
- Q.Clear与现行EARL推荐算法计算的DS存在显著差异。
- 5例Q.Clear判为非缓解者的患者被现行EARL推荐判为缓解者。
- 现行EARL推荐更倾向于将患者分类为缓解者。
核心结论
- 使用拟议的更新版EARL推荐相比现行推荐会显著改变DS分类。
- 在特定病例中,这种不一致会影响医疗治疗选择。
- 现行EARL推荐更常将患者分类为缓解者。
研究设计与样本
- 比较三种重建算法:Q.Clear(符合拟议更新版EARL推荐)及符合现行EARL推荐上下限的EARLlower和EARLupper。
- 半自动分割纵隔血池和肝脏,手动分割病灶,获取SUVmax和SUVpeak并计算DS。
主要发现
- 使用SUVmax时,Q.Clear与EARLlower/EARLupper的DS差异显著(两者p<0.0001)。
- 使用SUVmax时,EARLlower与EARLupper的DS差异不显著(p=0.102)。
- 使用SUVpeak时,Q.Clear与EARLlower差异显著(p=0.001)。
- 使用SUVpeak时,Q.Clear与EARLupper差异不显著(p=0.071),EARLlower与EARLupper差异不显著(p=0.102)。
- 5例Q.Clear判定的非缓解者(DS 4-5)在EARLlower/EARLupper下被归为缓解者(DS 1-3),SUVmax和SUVpeak均如此。
临床怎么用
- 临床解读淋巴瘤DS时需注意重建算法与EARL协调化版本对分类的影响。
- 算法差异可能导致缓解与未缓解判定不一致,进而影响治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Deauville score (DS) is a clinical tool, based on the comparison between lesion and reference organ uptake of 18F-fluorodeoxyglucose (FDG), used to stratify patients with lymphoma into categories reflecting their disease status. With a plethora of positron emission tomography with computed tomography (PET-CT) hard- and software algorithms, standard uptake value (SUV) in lesions and reference organs may differ which affects DS classification and therefore medical treatment. The EANM Research Ltd. (EARL) harmonization program from the European Association of Nuclear Medicine (EANM) partly mitigates this issue, but local preferences are common in clinical practice. We have investigated the discordance in DS calculated from patients with lymphoma referred for 18F-FDG PET-CT reconstructed with three different algorithms: the newly introduced block-sequential regularization expectation-maximization algorithm commercially sold as Q. Clear (QC, GE Healthcare, Milwaukee, WI, USA), compliant with the newly proposed updated EARL recommendations, and two settings compliant with the current EARL recommendations (EARLlower and EARLupper, representing the lower and upper limit of the EARL recommendations). METHODS: Fifty-two patients with non-Hodgkin and Hodgkin lymphoma were included (18 females and 34 males). Segmentation of mediastinal blood pool and liver were semi-automatically performed, whereas segmentation of lesions was done manually. From these segmentations, SUVmax and SUVpeak were obtained and DS calculated. RESULTS: There was a significant difference in DS between the QC algorithm and EARLlower/EARLupper (p < 0.0001 for both) but not between EARLlower and EARLupper (p = 0.102) when SUVmax was used. For SUVpeak, there was a significant difference between QC and EARLlower (p = 0.001), but not for QC vs EARLupper (p = 0.071) or EARLlower vs EARLupper (p = 0.102). Five non-responders (DS 4-5) for QC were classified as responders (DS 1-3) when EARLlower/EARLupper was used, both when SUVmax and SUVpeak were investigated. CONCLUSION: Using the proposed updated EARL recommendations compared with the current recommendations will significantly change DS classification. In select cases, the discordance would affect the choice of medical treatment. Specifically, the current EARL recommendations were more often prone to classify patients as responders.
引用
- Ly J, Minarik D, Edenbrandt L, et al. The use of a proposed updated EARL harmonization of 18F-FDG PET-CT in patients with lymphoma yields significant differences in Deauville score compared with current EARL recommendations. EJNMMI Res. 2019. PMID: 31346805. doi:10.1186/s13550-019-0536-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。